MAPT and amyloidosis: For example, several biomarker studies have shown differential risk and associations between amyloid burden measured from PET and cognitive decline and/or impairment.44-46 Our results suggest that these mixed findings are likely at least partly explained by the difference in when people develop amyloid pathology during their lifetime and when pathophysiologic tau hyperphosphorylation and aggregation occurs relative to amyloid onset.